Free Trial
→ Trump's Law S.1582: $21T Dollar Revolution Coming (From Brownstone Research) (Ad)tc pixel Free HBIO Stock Alerts
NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

Harvard Bioscience logo
$0.44 0.00 (-0.43%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$0.45 +0.01 (+1.90%)
As of 09/12/2025 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

About Harvard Bioscience Stock (NASDAQ:HBIO)

Key Stats

Today's Range
$0.43
▼
$0.46
50-Day Range
$0.40
▼
$0.57
52-Week Range
$0.28
▼
$3.04
Volume
291,685 shs
Average Volume
464,562 shs
Market Capitalization
$19.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00
Consensus Rating
Moderate Buy

Company Overview

Harvard Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

HBIO MarketRank™: 

Harvard Bioscience scored higher than 79% of companies evaluated by MarketBeat, and ranked 198th out of 670 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harvard Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    Harvard Bioscience has a consensus price target of $2.00, representing about 352.9% upside from its current price of $0.44.

  • Amount of Analyst Coverage

    Harvard Bioscience has only been the subject of 1 research reports in the past 90 days.

  • Read more about Harvard Bioscience's stock forecast and price target.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harvard Bioscience is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harvard Bioscience is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Harvard Bioscience has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Harvard Bioscience's valuation and earnings.

  • Percentage of Shares Shorted

    2.00% of the float of Harvard Bioscience has been sold short.

  • Short Interest Ratio / Days to Cover

    Harvard Bioscience has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

  • Change versus previous month

    Short interest in Harvard Bioscience has recently increased by 27.88%, indicating that investor sentiment is decreasing significantly.

  • Dividend Yield

    Harvard Bioscience does not currently pay a dividend.

  • Dividend Growth

    Harvard Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.00% of the float of Harvard Bioscience has been sold short.

  • Short Interest Ratio / Days to Cover

    Harvard Bioscience has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

  • Change versus previous month

    Short interest in Harvard Bioscience has recently increased by 27.88%, indicating that investor sentiment is decreasing significantly.

  • News Sentiment

    Harvard Bioscience has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Computer and Technology companies.

  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Harvard Bioscience this week, compared to 16 articles on an average week.

  • Search Interest

    5 people have searched for HBIO on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

  • Insider Buying vs. Insider Selling

    In the past three months, Harvard Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Harvard Bioscience is held by insiders.

  • Percentage Held by Institutions

    80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harvard Bioscience's insider trading history.
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HBIO Stock News Headlines

Benchmark Lowers Harvard Bioscience (NASDAQ:HBIO) Price Target to $2.00
September 11 at 3:39 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30322390
Resilient Performance and Strategic Growth Drive Buy Rating for Harvard Bioscience Amid Market Challenges
September 10 at 7:50 AM  |  tipranks.comhttps://www.tipranks.com/news/ratings/resilient-performance-and-strategic-growth-drive-buy-rating-for-harvard-bioscience-amid-market-challenges-ratings?utm_source=marketbeat.com&utm_medium=referral
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
September 13 at 2:00 AM  |  Brownstone Research (Ad)
Harvard Bioscience Appoints Stephen DeNelsky to Board
September 9, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/harvard-bioscience-appoints-stephen-denelsky-to-board?utm_source=marketbeat.com&utm_medium=referral
Harvard Bioscience, Inc. Appoints Stephen DeNelsky to Board of Directors
September 9, 2025  |  quiverquant.comQ
Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors
September 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/09/3146739/11635/en/harvard-bioscience-announces-appointment-of-stephen-denelsky-to-board-of-directors.html
Harvard dropouts to launch ‘always on’ AI smart glasses that listen and record every conversation
August 21, 2025  |  msn.comhttps://www.msn.com/en-us/news/technology/harvard-dropouts-to-launch-always-on-ai-smart-glasses-that-listen-and-record-every-conversation/ar-AA1KTb2t
Belgium’s Crown Princess Elisabeth Will Continue Her Studies at Harvard University This Fall
August 19, 2025  |  msn.comhttps://www.msn.com/en-us/lifestyle/lifestyle-buzz/belgiums-crown-princess-will-return-to-harvard-this-fall/ar-AA1KKPkd
See More Headlines

HBIO Stock Analysis - Frequently Asked Questions

Harvard Bioscience's stock was trading at $2.11 at the beginning of 2025. Since then, HBIO shares have decreased by 79.1% and is now trading at $0.4416.

Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its quarterly earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The medical instruments supplier had revenue of $29.66 million for the quarter, compared to the consensus estimate of $28.10 million. Harvard Bioscience had a negative net margin of 64.68% and a negative trailing twelve-month return on equity of 5.64%.

Harvard Bioscience subsidiaries include these companies: Data Sciences International.

Top institutional investors of Harvard Bioscience include AMH Equity Ltd (7.94%), Harvey Partners LLC (4.81%), Geode Capital Management LLC (1.00%) and Pasadena Private Wealth LLC (0.55%).
View institutional ownership trends.

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include YETI (YETI), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Alphabet (GOOG), Stag Industrial (STAG) and Tesla (TSLA).

Company Calendar

Last Earnings
11/02/2021
Today
9/13/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Computer and Technology
Industry
INSTRU - SCIENTFC
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CIK
1123494
Web
www.harvardbioscience.com
Phone
(508) 893-8999
Fax
508-429-5732
Employees
490
Year Founded
1901

Price Target and Rating

Average Price Target for Harvard Bioscience
$2.00
High Price Target
$2.00
Low Price Target
$2.00
Potential Upside/Downside
+352.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.40 million
Net Margins
-64.68%
Pretax Margin
-64.17%
Return on Equity
-5.64%
Return on Assets
-2.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.81
Quick Ratio
0.41

Sales & Book Value

Annual Sales
$94.14 million
Price / Sales
0.21
Cash Flow
$0.10 per share
Price / Cash Flow
4.39
Book Value
$1.45 per share
Price / Book
0.30

Miscellaneous

Outstanding Shares
44,530,000
Free Float
40,301,000
Market Cap
$19.66 million
Optionable
Optionable
Beta
1.54

Social Links

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:HBIO) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...
Stansberry Research | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel
October 16 Changes the Microchip Game — and Investing
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...
Banyan Hill Publishing | Sponsoredtc pixel
Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...
Investors Alley | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...
Paradigm Press | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel